ORVILLE JACOB A, EVP and General Manager of Screening, has demonstrated a clear selling bias in his recent insider trading activity, as evidenced by SEC Form 4 filings. Over the course of 26 transactions spanning two companies—Abbott Laboratories (ABT) and Exact Sciences Corporation (EXAS)—Orville has not recorded any purchases, while his total sell value amounts to $7,461,032.79. The majority of this activity is concentrated in EXAS, where he has executed multiple sales, including a notable transaction on November 19, 2025, valued at $375,000. Additionally, Orville has engaged in a series of derivative transactions involving EXAS, primarily through exercises and dispositions of stock options, with significant values such as $1,377,319.14 and $2,034,974.52 on December 23, 2025.
The pattern of Orville’s trades suggests a focus on liquidating holdings rather than acquiring new positions. His most recent activity, as of March 23, 2026, includes derivative transactions in both ABT and EXAS, though these entries lack monetary values, indicating they may involve non-cash adjustments or transfers. The absence of buy transactions and the consistent selling activity highlight a strategic reduction in his equity exposure, particularly in EXAS. This trend aligns with his role as an executive, where such transactions may be part of broader financial planning or portfolio management. The data underscores Orville’s preference for divestment over investment in recent years, reflecting a cautious approach to his equity holdings.
AI-assisted summary